Ÿnsect, the French mealworm company that raised over €600 million and was widely cited as the template for industrial-scale insect protein, was ordered into judicial liquidation by a French court in December 2025. Its flagship facility near Dole will close. A smaller pilot site continues, focused on frass and fertiliser.
The collapse has prompted a wave of industry commentary. Most of it is from investors and venture journalists. This note is for UK producers.
What actually happened
Ÿnsect’s model was built on the assumption that mealworm protein could compete on price with soy and fishmeal at industrial scale. The unit economics did not work out. Insects cost two to ten times as much as soy protein per kilogram of protein output. The gap was not closed by automation. Capital markets, which had funded the bet on that gap closing, stopped funding it.
The wider funding picture supports this: global insect protein investment fell from $472M in 2022 to $170M in 2024.
What this does not mean
Ÿnsect’s collapse is not evidence that mealworm farming does not work. It is evidence that one specific model (high-capex, fully automated, commodity feed market, single-product, VC-funded) is broken at current prices.
What it does mean for UK producers
Three things change after Ÿnsect’s failure, all of them in favour of diversified SMB operators:
1. The industrial template is gone. There is no longer a “scale to Ÿnsect size” pathway that investors will fund. This removes a category of competitor that could have undercut SMB producers on price once at scale. The market is back to players who can survive on realistic margins.
2. Frass is a primary revenue stream, not an afterthought. The surviving Ÿnsect entity is specifically focused on frass and fertiliser. This is not coincidence. Frass is a relatively high-value, low-substitution product where insect producers have a genuine advantage. For UK producers, the pending Defra UK Fertilising Product Regulations outcome matters more now than it did before December 2025.
3. The Academy and Advisory market just got bigger. Ÿnsect trained a significant number of mealworm facility operators. Some of those operations will be looking for a new knowledge base and operational support. The knowledge gap in this sector has not shrunk; it has grown.
The regulatory angle
Ÿnsect’s collapse happened not because of regulation, but in spite of favourable EU regulation (T. molitor was fully approved for human food in the EU). Regulation was not the bottleneck. Cost was. UK producers should not be waiting for better regulation before investing in operations. They should be building disciplined operations that can survive on current market conditions, with regulatory improvement as upside.
That said, the frass revenue stream that is now front-of-mind for the industry does depend on regulatory clarity. The Defra consultation outcome (expected H2 2026) will determine whether UK producers can formally market frass as a regulated fertiliser product or continue working around the current grey area.